Scarica l'app Stockscreener
8.87
0.11%
-0.01
Dopo l'orario di chiusura:
8.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.88
Aprire:
$8.7
Volume 24 ore:
1.10M
Relative Volume:
1.08
Capitalizzazione di mercato:
$841.87M
Reddito:
$823.60M
Utile/perdita netta:
$-116.00M
Rapporto P/E:
-6.8231
EPS:
-1.3
Flusso di cassa netto:
$-107.30M
1 W Prestazione:
-11.12%
1M Prestazione:
-17.33%
6M Prestazione:
-67.62%
1 anno Prestazione:
-58.40%
Intervallo 1D:
$8.5332
$9.02
Intervallo di 1 settimana:
$8.5332
$10.14
Portata 52W:
$8.5332
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Nome
Myriad Genetics Inc
Settore
Industria
Telefono
801-584-3600
Indirizzo
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Confronta MYGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
8.87 | 841.87M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
497.60 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.00 | 150.17B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
419.95 | 34.36B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
116.98 | 33.45B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
176.30 | 31.62B | 15.41B | 1.37B | 2.11B | 7.50 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-12 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Iniziato | Craig Hallum | Buy |
| 2024-12-10 | Iniziato | UBS | Neutral |
| 2024-12-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Underperform |
| 2024-05-08 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Ripresa | Piper Sandler | Neutral |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Underweight |
| 2023-05-23 | Aggiornamento | Goldman | Sell → Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Iniziato | Stephens | Equal-Weight |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Sell |
| 2019-09-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Downgrade | Needham | Strong Buy → Hold |
| 2019-07-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-03-12 | Reiterato | Needham | Strong Buy |
| 2019-01-03 | Iniziato | Needham | Strong Buy |
| 2018-11-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Iniziato | Goldman | Sell |
| 2018-01-22 | Reiterato | Barclays | Equal Weight |
| 2018-01-05 | Iniziato | BTIG Research | Buy |
| 2017-10-02 | Ripresa | Leerink Partners | Mkt Perform |
| 2017-08-09 | Reiterato | Barclays | Equal Weight |
| 2017-02-08 | Aggiornamento | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Iniziato | Deutsche Bank | Sell |
| 2016-10-10 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
Mostra tutto
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Cancer Biomarkers Market Set to Witness Significant Growth - openPR.com
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now? - MSN
Myriad Genetics stock hits 52-week low at $9.36 amid challenges By Investing.com - Investing.com South Africa
Myriad Genetics stock hits 52-week low at $9.36 amid challenges - Investing.com Australia
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Press Release Service: United States Molecular Diagnostics Market Forecast Report and Company Analysis 2025-2033 Featuring F Hoffmann-la Roche, Illumina, Hologic, Agilent, Qiagen, Myriad Genetics, Abbott, Danaher, BD & CoResearchAndMarkets.co - CRISPR Medicine News
Trend Tracker for (MYGN) - Stock Traders Daily
Global Preventive Healthcare Technologies And Services Market - openPR
The Future of Genetic Testing: Industry Growth, Trends & Key - openPR
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31% - Simply Wall St
Myriad Genetics upgraded at Piper Sandler on balanced risk reward setup - MSN
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade - Benzinga
Myriad Genetics (MYGN) Stock Jumps on Analyst Upgrade - GuruFocus.com
Myriad Genetics Shares Rise After Upgrade From Piper Sandler -March 12, 2025 at 02:53 pm EDT - Marketscreener.com
Myriad Genetics stock upgraded at Piper Sandler (MYGN:NASDAQ) - Seeking Alpha
Why Are Myriad Genetics (MYGN) Shares Soaring Today - Yahoo Finance
This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Medical Equipment Stock Jumps on Upgrade - Schaeffers Research
Buy Rating on Myriad Genetics: Strategic Changes and Growth Potential Amid Challenges - TipRanks
Piper Sandler upgrades Myriad to 'overweight' on CEO change - TradingView
Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50 - Marketscreener.com
Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler - TipRanks
Morgan Stanley cuts Myriad Genetics stock target to $16 from $21 - Investing.com Canada
(MYGN) On The My Stocks Page - Stock Traders Daily
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Myriad Genetics at Leerink Global Healthcare Conference: Strategic Growth Amid Challenges - Investing.com Canada
Myriad Genetics stock hits 52-week low at $9.74 amid challenges - Investing.com Canada
Myriad Genetics stock hits 52-week low at $9.74 amid challenges By Investing.com - Investing.com South Africa
Myriad Genetics, Inc. to Host Earnings Call - ACCESS Newswire
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.
Piper Sandler Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $11.50 - Defense World
US$19.13: That's What Analysts Think Myriad Genetics, Inc. (NASDAQ:MYGN) Is Worth After Its Latest Results - Yahoo Finance
Analyst Expectations For Myriad Genetics's FutureMyriad Genetics (NASDAQ:MYGN) - Benzinga
Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes - TipRanks
Myriad Genetics (NASDAQ:MYGN) Announces Quarterly Earnings Results - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Lowered to Hold Rating by StockNews.com - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Sets New 12-Month Low on Disappointing Earnings - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Earns "Outperform" Rating from Raymond James - MarketBeat
UBS Group Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat
Leerink Partnrs Forecasts Myriad Genetics Q2 Earnings - MarketBeat
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools - GlobeNewswire
Myriad Genetics Partners With Gabbi To Offer Breast Cancer Risk Assessment & Care Solution - Nasdaq
Myriad Genetics Collaborates with Gabbi to Enhance Breast Cancer Risk Assessment and Care Services - Nasdaq
How Myriad Genetics' New Telehealth Partnership Could Transform Breast Cancer Detection - StockTitan
Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results - Simply Wall St
Myriad Genetics price target lowered to $19 from $27 at Raymond James - MSN
Myriad Genetics Inc Azioni (MYGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
1.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):